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Abstract
Prostacyclin and analogues are successfully used in the treatment of pulmonary arterial hypertension 
(PAH) due to their vasodilatory effect on pulmonary arteries. Besides vasodilatory effect, prostacyclin 
analogues inhibit platelets, but their antiplatelet effect is not thoroughly established. The antiplatelet 
effect of prostacyclin analogues may be beneficial in case of increased risk of thromboembolic events, or 
undesirable in case of increased risk of bleeding. Since prostacyclin and analogues differ regarding their 
potency and form of administration, they might also inhibit platelets to a different extent. This review 
summarizes the recent evidence on the antiplatelet effects of prostacyclin and analogue in the treatment 
of PAH, this is important to consider when choosing the optimal treatment regimen in tailoring to an 
individual patients’ needs. (Cardiol J 20XX; XX, X: xx–xx)
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Introduction
Since 1935 when prostaglandin was isolated 
for the first time [1], many scientists have focused 
on a thorough study of arachidonic acid transforma-
tion products and their various biological functions. 
One of the major prostaglandins is prostacyclin 
(PGI2), which was discovered by John R. Vane in 
1976 [2]. Endogenous PGI2 binds to prostacyclin 
receptor (IP) on pulmonary vessels smooth muscle 
cells and platelets. Activated IP receptor induces 
production of cyclic adenosine monophosphate 
(cAMP), which activates protein kinase A (PKA) 
and results in smooth muscle relaxation, inhibi-
tion of platelet aggregation and reduction of cell 
proliferation [3]. Synthetic PGI2 analogues have 
a similar effect on cells as does natural PGI2. 
Nowadays, PGI2 and its analogues are being used 
due to their vasodilating, antithrombotic and an-
tiproliferative effects [4]. The main indication for 
PGI2 and analogues is advanced pulmonary arterial 
hypertension (PAH) and peripheral vascular disor-
ders [5]. Treprostinil, iloprost and beraprost are the 
most frequently used prostacyclin analogues [4]. 
Selexipag is a non-prostanoid IP receptor agonist 
and a promising new alternative for classic PGI2 
analogues [6]. 
As PGI2 analogues vary depending on the 
way of administration, pharmacokinetics, binding 
and affinity for IP receptors, they may also inhibit 
platelets to a different extent [5]. These differences 
result in various side effects and complications 
associated with the of PGI2 analogues and impli-
cate the need to tailor the treatment according to 
a patient’s individual needs. Because the inten-
sity of antiplatelet effect of PGI2 analogues have 
not been clarified, choosing the best therapeutic 
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a history of thrombosis or bleeding remains chal-
lenging. This review (i) describes the role of PGI2 
in hemostasis, (ii) summarizes the recent evidence 
on the antiplatelet effect of PGI2 analogues in the 
treatment of PAH, and (iii) provides recommen-
dations regarding the choice of the optimal PGI2 
analogue in case of thrombosis or bleeding. 
Role of prostacyclin in hemostasis
PGI2 plays a prominent role in hemostasis, 
both due to its effect on vascular endothelium, 
smooth muscle cells and platelets. When a blood 
vessel wall is damaged, collagen and von Wille-
brand factor (vWF) are exposed enabling platelets 
adherence to the subendothelium and granule 
content release [7]. Thromboxane A2 (TxA2) and 
adenosine diphosphate (ADP) released from, or 
produced by activated platelets contribute to plate-
let aggregation, which temporarily repairs vascular 
injury. ADP also induces the conformation change 
of glycoprotein (GP) IIb/IIIa type receptor, allowing 
binding of fibrinogen to GP IIb/IIIa and cross-link-
ing of the adjacent platelets. The released calcium 
ions (Ca2+) bind to phospholipids that are exposed 
on the surface of activated platelets and provide 
a co-factor for the assembly of coagulation factors, 
facilitating thrombus formation [8]. The processes 
of primary hemostasis are counteracted by PGI2, 
which is a thromboxane receptor antagonist. The 
main task of PGI2 is to limit the coagulation to 
the small area where it is needed, and to sustain 
patency of the blood vessel [9]. 
Following platelet-rich thrombus formation, 
further steps include activation of plasma coagula-
tion factors and formation of crosslinked fibrin by 
two pathways: extrinsic and intrinsic. The extrinsic 
pathway is activated by the tissue factor (TF) ex-
posed by vessel injury and released from platelets, 
which is necessary for activation of factor VII. The 
complex consisting of Ca2+, TF and factor VII can 
then activate factor X, which starts the common 
pathway [10]. In the intrinsic pathway, factor XII is 
activated by contact with the damaged vascular sur-
face, high molecular weight kininogen and kallikrein. 
This complex initiates the cascade of activation of 
factor XI and IX. The next step is the activation of 
factor X, which starts the common pathway. Finally, 
factors Xa, Va and Ca2+ form a complex that converts 
prothrombin to thrombin, which then converts 
fibrinogen to fibrin to form a fibrin polymer. After 
that, plasma transglutaminase (factor XIII) stabilises 
the clot. Although PGI2 is not directly involved in 
clot formation, appropriate platelet aggregation is 
a prerequisite for clotting. Hence, PGI2 may affect 
secondary hemostasis and clot formation as well.
Prostacyclin receptors 
Prostacyclin receptors (IP) are seven-trans-
membrane G protein-coupled receptors, exposed 
on vascular smooth muscle cells and platelets [11]. 
The main characteristics of the IP receptors are sum-
marized in Table 1. There are four types of IP recep-
tors on platelets: IP, DP, TP, and EP3. The IP and DP 
receptors have anti-aggregatory effects, whereas the 
TP, EP3 have pro-aggregatory effects [12].
Figure 1 shows the function of IP and DP re-
ceptors. The IP receptor works in two ways. First, 
it activates Gs protein, associated with adenylyl 
cyclase (AC) to produce cAMP [13], resulting 
in phosphorylation of the vasodilator-stimulated 
phosphoprotein (VASP) by protein kinase A. VASP 
suppresses the activation of the membrane GP IIb/ 
/IIIa, thus preventing platelet aggregation [14]. 
Second, IP activates Gq protein [15]. Activation of 
Gq protein stimulates phospholipase C to synthe-
size second messengers which increases the intra-
cellular Ca2+ concentration. Increases Ca2+ reduces 
the amount of cAMP, which might facilitate platelet 
aggregation [16]. However, the Gq-mediated effect 
of PGI2 is less significant, so that the net effect of 
PGI2 binding to IP receptor is anti-aggregatory. The 
DP receptor activates Gs protein only, therefore 
raising the intracellular cAMP concentration and 
potentiating platelet inhibition.
Table 1. Receptors for prostacycline and its analogues on platelets.
Receptor G-protein coupled Effect of activation Agonist
DP [25, 49] Gs cAMP≠ epoprostenol, iloprost, treprostinil
IP [23, 24, 25, 48] Gs > Gq cAMP≠ epoprostenol, iloprost, treprostinil,  
beraprost, selexipag
TP [22] Gq > Gs = Gi cAMPØØ iloprost
EP3 [23, 24] Gi > Gq = Gs cAMPØ epoprostenol, iloprost, beraprost
cAMP — cyclic adenosine monophosphate
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TP receptor affects the activity of three 
G proteins: Gq protein strongly, and both Gi and Gs 
in a less significant way. Since the effect of TP on 
Gi and Gs are contradictory, the net effect of this 
receptor is executed via Gq protein, resulting in 
reduced cAMP concentration and a pro-aggregatory 
effect [17, 18]. However, the TP receptor can also 
form heterodimers with the TP receptor [19]. The 
IP-TP heterodimer function is similar to the IP re-
ceptor (anti-aggregatory), since the TP compound 
is overpowered. The EP3 receptor activates the 
same G proteins as TP receptor, but most signifi-
cantly the Gi protein, resulting in reduced cAMP 
and platelet aggregation [20].
Due to the fact that the IP receptors have both 
anti- and pro-aggregatory modes of action, the net 
clinical effect (thrombosis and bleeding) of PGI2 and 
analogues are difficult to predict. Recently, there 
has been a search for a substance, which would 
specifically bind to the IP receptor, resulting in the 
introduction of selexipag [21]. Selexipag has a much 
higher affinity to platelet-inhibiting receptors (IP 
and DP), and none to platelet-activating receptors 
(TP and EP3). However, whether this specificity is 
associated with a higher bleeding tendency remains 
to be investigated.
Differences in pharmacodynamics  
and pharmacokinetics of  
prostacyclin and analogues
PGI2 and analogues are available in paren-
teral and oral form. Different routes of adminis-
tration result in differing pharmacokinetics of each 
drug. PGI2 and analogues are primarily metabolized 
by cytochromes P450 in the liver, especially by 
CYP2C8. Selexipag is the only PGI2 analogue which 
has an active metabolite. Short half-life of PGI2 and 
analogues often requires continuous infusions by 
external or implantable intravenous infusion pumps. 
Epoprostenol, iloprost and beraprost bind both to the 
antiaggregatory IP and DP receptors and to the pro-
aggregatory EP3 [22–24]. Iloprost also binds to the 
pro-aggregatory TP receptor [22]. Treprostinil binds 
only to the anti-aggregatory IP and DP receptors 
[25]. Selexipag is a specific IP receptor agonist [24]. 
Consequently, the route of administration, metabo-
lism of PGI2 and analogues and their binding profile 
may define their side effects, including thrombosis 
and bleeding. The comparison of pharmacokinet-
ics, pharmacodynamics and side effects of the most 
commonly used drugs PGI2 analogue are thoroughly 
summarized in Table 2.
Figure 1. Effects of activation of IP and DP for prosta-
cyclin receptors on platelets; abbreviations — see text.
Table 2. Comparison of pharmacokinetics, side effects, contraindications of the most commonly used 
drugs which target the prostacyclin pathway.
Drug1 Route of  
administration
Pharmacokinetics Side effects related  
to the route of  
administration
Side effects not related 
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Table 2 (cont.). Comparison of pharmacokinetics, side effects, contraindications of the most commonly 
used drugs which target the prostacyclin pathway.
Drug1 Route of  
administration
Pharmacokinetics Side effects related  
to the route of  
administration
Side effects not related 
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1Contraindications to the use of any of the PGI2 analogues: heart failure with reduced left ventricular ejection fraction, severe hepatic impairment 
(Child Pugh class C), concomitant use of strong inhibitors of CYP2C8 (e.g. gemfibrozil), hypersensitivity to the drug; 2The preferred administration 
route of treprostinil; 3External or implantable intravenous infusion pump
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Thrombosis and bleeding during  
prostacyclin and analogues therapy
Epoprostenol
Epoprostenol not only inhibits platelet reac-
tivity, but also decreases platelet count [26]. It 
was reported that epoprostenol induces thrombo-
cytopenia in 35–65% of patients [27, 28]. Hence, 
bleeding complications may occur during treatment 
with epoprostenol. For example, among 31 patients 
with idiopathic PAH (iPAH), who were treated both 
with epoprostenol and anticoagulants, 11 bleeding 
episodes occurred (35%), 9 of which were alveo-
lar hemorrhages [29]. However, the concomitant 
anticoagulation may have biased the results. In 
a prospective, randomized, multicenter, open-label 
clinical trial which compared the efficacy of the 
continuous intravenous infusion of epoprostenol 
on top of conventional therapy versus conventional 
therapy alone in 81 patients with severe iPAH 
(New York Heart Association [NYHA] class III or 
IV), 4 out of 41 patients treated with epoprostenol 
(9.8%) experienced bleeding at the catheter site, 
and 1 experienced a thrombotic event (paradoxi-
cal embolism) [30]. However, the rate of bleeding 
and thrombotic events in the control group were 
not reported [30]. Herrero et al. [31] described 3 
cases of severe PAH in pregnancy, treated with 
epoprostenol and complicated with thrombocy-
topenia, caesarean section wound hematoma and 
postpartum hemorrhage. Louis et al. [32] described 
3 cases of nontraumatic subdural hematomas dur-
ing treatment with PGI2 and analogues (1 with 
epoprostenol, 1 with iloprost and 1 with trepro-
stinil). However, all episodes occurred in patients 
with low platelet count, and all patients received 
concomitant anticoagulantion, making it impossible 
to determine the real cause of bleeding events. Al-
together, it seems that epoprostenol may increase 
the risk of bleeding. However, since the hitherto 
studies were prone to confounding factors such 
concomitant anticoagulation, lack of control group 
and small sample size, more research is needed to 
draw firm conclusions.
Treprostinil
In a prospective study including 860 patients 
with PAH treated with subcutaneous treprostinil 
with or without warfarin, the incidence of bleed-
ing was 35% (206/590) in patients on combined 
therapy, and 42% (112/270) in patients only re-
ceiving treprostinil (13 severe, 29 moderate and 
70 mild bleeding episodes) [33, 34]. Similarly, in 
a double-blind, placebo-controlled, multicenter 
trial comprising 470 patients with PAH, either 
idiopathic or associated with connective tissue 
disease or congenital heart disease, 34% patients 
experienced infusion site bleeding or bruising with 
treprostinil (79/233), and as much as 44% with 
a placebo (102/236) during 12 weeks of treatment 
[35]. The incidence of gastrointestinal (GI) bleed-
ing was only 0.01% (3/233) on treprostinil, and 
2 out of 3 patients who experienced GI bleeding had 
increased international normalized ratio (INR; 3.1 
and 4.0). In another study, the estimated incidence 
of GI bleeding with subcutaneous administration 
of treprostinil was 1.3% [36]. However, in a case 
series of 5 infants with PAH associated with chronic 
lung disease and treated with subcutaneous trepro-
stinil, there were no bleeding or bruising episodes 
[37]. Altogether, although the treatment with 
subcutaneous treprostinil seems to be associated 
with relatively high rate of small and local bleed-
ing, this rate was comparable to the placebo, which 
implies an effect of the infusion system, but not the 
drug itself. Recently, a double-blind, phase 3, ran-
domised controlled trial was conducted, where 105 
patients with chronic thromboembolic pulmonary 
hypertension, classified as non-operable, or with 
persistent or recurrent pulmonary hypertension 
after pulmonary endarterectomy, on chronic antico-
agulation were divided into high-dose (~30 ng/kg/ 
/min, n = 53) and low-dose (~3 ng/kg/min, n = 52) 
of subcutaneously administered treprostinil. There 
were no severe bleeding adverse events in the low 
dose group and single episodes of hemoptysis and 
hematoma in the high-dose group. Noteworthy, 
3 (5.8%) episodes of epistaxis were observed in 
the low-dose group, and only 1 (1.9%) episode in 
the high-dose group, implying that the bleeding on 
subcutaneous treprostinil is not dose-related [38].
Besides subcutaneous infusion, which is the 
preferred administration route of treprostinil, it 
may also be administered intravenously. In a retro-
spective, multi-center study involving 12 patients 
with PAH treated with subcutaneous infusion of 
treprostinil, with intolerable pain at the infusion 
site, an intravenous infusion pump was implanted. 
During the postoperative period, 4 (33%) patients 
experienced a small hematoma in the implantation 
site that required a single evacuation by puncture. 
In 1 patient, puncturing of the pump area was 
required 3 times due to a recurrence of the he-
matoma. However, this patient had concomitant 
coagulopathy due to splenomegaly associated with 
liver cirrhosis resulting in thrombocytopenia [39]. 
However, intravenous infusion might increase the 
bleeding risk, although no head-to-head compari-
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sons between the routes of treprostinil administra-
tion are available.
The efficacy and safety of inhaled treprostinil 
was evaluated in 9 patients with pulmonary hy-
pertension and concomitant chronic obstructive 
pulmonary disease [40]. After 16 weeks of treat-
ment, none of the patients experienced a clinically 
significant bleeding episode, and 1 patient reported 
blood in sputum [40]. Hence, it seems that trepro-
stinil administered in inhalation may be safer than 
administered subcutaneously or intravenously, but 
the heterogeneity and small sample size of the 
study groups require caution when interpreting 
the results.
Iloprost
Intravenous iloprost was investigated in 
a prospective study in 30 patients with systemic 
sclerosis, leading to only 1 bleeding episode (in-
tracranial hemorrhage) during 3 years follow-up. 
The same patient had previously suffered a central 
retinal vein thrombosis [41]. Intravenous iloprost 
was also evaluated in a randomized, placebo-
-controlled study in 300 patients as adjuvant to 
surgery for acute ischemia of lower limbs, with 
similar incidences of bleeding in patients treated 
with iloprost and placebo at 3 month follow-up [42]. 
Inhaled iloprost, in turn, was used to treat PAH 
due to preterm rupture of foetal membranes in 
4 extremely low-birthweight neonates (23– 
–25 weeks gestation, 448–645 gram weight) un-
der spontaneous breathing, supported by nasal 
continuous positive airway pressure. There was 
no prolonged bleeding incident noted in any of 
the patients [43]. Altogether, it seems that both 
intravenous and inhaled iloprost may be safe, but 
there is too little data to draw firm conclusions.
Beraprost
In a prospective clinical trial comprising 308 
patients with acute ischemic stroke, patients were 
divided into an experimental group (n = 154) 
treated with beraprost (40 μg, twice daily) on top 
of acetylsalicylic acid (100 mg, once daily) and 
a control group (n = 154) treated with acetylsalicylic 
acid only (100 mg, once daily). Both treatment regi-
mens were administered orally and continued for 
6 months after hospital discharge. At 6 months, the 
coagulation parameters (activated partial thrombo-
plastin time, prothrombin time, INR and fibrinogen) 
and bleeding rates were comparable between the 
groups [44]. Similarly, in a prospective clinical 
study including 55 patients with end-stage renal 
disease on hemodialysis, beraprost (n = 23, 120 µg 
per day) did not increase the rate of bleeding, 
compared to the standard therapy (n = 32) [45]. 
Altogether, the preliminary data implicate that 
treatment with beraprost does not increase the 
rate of bleeding, but this conclusion needs to be 
confirmed in future studies.
Selexipag
The GRIPHON (PGI2 Receptor Agonist In 
Pulmonary Arterial Hypertension) study took 
place in 181 centres and was the biggest clinical 
trial in patients with PAH. In this double-blind, 
randomized, placebo-controlled study, the efficacy 
and safety of selexipag was investigated in 1156 
patients in different stadiums of PAH [21]. Selex-
ipag did not increase the rate of bleeding, including 
gastrointestinal hemorrhage [46], and did not have 
a substantial effect on platelet aggregation [47]. 
Based on this study, selexipag seems to be a safe 
treatment regimen in PAH.
Discussion
PGI2 and analogues are widely used in treat-
ment of PAH, but their antiplatelet effect and re-
lated bleeding complications are still insufficiently 
investigated. Experimental data suggests that the 
IP and DP receptors have antiaggregatory effects, 
whereas the TP and EP3 have pro-aggregatory 
effects by modulating the intracellular concentra-
tion of cAMP [23–25, 48, 49]. Consequently, drugs 
which bind to the IP and DP receptors only (trepro-
stinil, selexipag) are expected to have higher an-
tiplatelet activity than those which bind to IP, DP 
and EP3 receptors (epoprostenol, beraprost) and to 
all receptors (iloprost). However, data from clinical 
studies do not always comply with experimental 
insights. For example, it seems that epoprostenol 
and treprostinil may increase bleeding risk, es-
pecially if treprostinil is administered subcutane-
ously or intravenously [33–35, 39]. In addition, 
a randomized controlled trial on 105 patients treat-
ed with treprostinil administered subcutaneously 
showed that the frequency of bleeding complica-
tions was not dose-related [38]. On the contrary, 
no increased bleeding tendency was seen with 
iloprost, beraprost and selexipag. Hence, one could 
consider avoiding epoprostenol and treprostinil, 
and rather choose iloprost, beraprost or selexipag 
in patients with increased bleeding risk, or with 
a history of bleeding. However, since the hitherto 
studies were prone to confounding factors such 
concomitant anticoagulation, lack of control group, 
small sample size and heterogeneity, the previous 
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results should be interpreted with caution, and 
more evidence is needed to draw firm conclusions. 
Especially, large-scale, randomized clinical studies 
to compare different PGI2 analogues head-to-head 
are urgently needed to determine the optimal 
treatment regimen in patients with increased risk 
of thrombosis or bleeding, tailored to an individual 
patients’ needs.
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